Analysts raised target for Pro Medicus stock to AUD 202.47

Published on 10/13/2026 at 01:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal year 2026 revenue reached AUD 261.70 million, up 22.90 percent year over year. Nine analysts rate Pro Medicus stock a Buy before November 25.

Key points in brief

Analysts raised the Pro Medicus target to AUD 202.47 from AUD 190.74 on September 4, 2026.
Fiscal year 2026 revenue reached AUD 261.70 million, up 22.90 percent from fiscal year 2025.
Pro Medicus had an AUD 17.6 billion market capitalization as of October 12, 2026.
The company will hold its annual general meeting on November 25, 2026.

Pro Medicus, AU000000PME8, Illustration mit AI erstellt.

Pro Medicus stock was assigned an AUD 202.47 target, up from AUD 190.74 on September 4, 2026, as Simply Wall St reported. The target increase frames a stock valued on October 12 at AUD 17.6 billion, while the latest euro quote appears separately below.

Capital Brief reported on September 23, 2026, that Pro Medicus had appointed Tim Reed as an independent non-executive director effective October 1, 2026. Reed previously led MYOB from 2008 to 2019 and later served as co-managing director of Potentia Capital.

Three results shaped the story

On February 13, 2026, first-half revenue reached AUD 124.80 million, up 28.00 percent from the first half of 2025, while earnings per share rose to AUD 1.64 from AUD 0.49, according to Simply Wall St.

On August 19, 2026, fiscal year 2026 revenue was AUD 261.70 million, up 23.00 percent from fiscal year 2025, while net income increased 130.00 percent to AUD 265.30 million, the same source reported. That comparison puts the target revision against a business that delivered rapid earnings growth in its latest completed fiscal year.

The September board appointment added a governance and software execution angle. Capital Brief said Reed brought more than 30 years of technology, strategy and investment experience to the board.

What does the target imply?

The AUD 202.47 target stands 6.15 percent above the previous AUD 190.74 target, calculated from the two figures reported by Simply Wall St. The counterweight is valuation: Simply Wall St listed 23 analysts covering Pro Medicus, with 14 contributing estimates to its model.

Market context also remains technical. The Bull reported an ASX price of AUD 168.37 on October 12, 2026, above the 30-day average of AUD 165.32 and the 200-day average of AUD 160.52. The same report placed the stock 24.37 percent lower year to date, showing why execution remains central to the valuation debate.

Annual meeting sets the next date

Pro Medicus is scheduled to hold its annual general meeting on November 25, 2026, according to Simply Wall St. The meeting follows fiscal year 2026 revenue of AUD 261.70 million and places board composition, contract execution and capital allocation alongside the revised target.

Euro quote remains dated

The last Lang & Schwarz quote stood at EUR 103.68 on October 12, 2026, at 11:00 p.m. CEST. The company is listed on the Australian Securities Exchange under PME, and its core business is medical imaging software and healthcare informatics.

The further course of trading is shown by the continuously updated real-time quote of Pro Medicus stock.